Ife



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2-17-06

Signature

David A Gass)

Docket No.: 19036/40796

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Yuka Matsui

Application No.: 10/561,629

Confirmation No.: N/A

Filed: 21 June 2004 as PCT/JP2004/008710

Art Unit: N/A

For: OPHTHALMIC COMPOSITION

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the applicant requests that the examiner in this matter consider the documents listed on the attached PTO/SB/08 during the prosecution of this application, and make them record so that they appear among the "References Cited" on any issued patent.

This Information Disclosure Statement is filed within three months of the U.S. filing (entry into national phase) date (37 CFR 1.97(b)(1)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

Application No.: 10/561,629 Docket No.: 19036/40796

1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art."

An English language abstract is provided for each Japanese language document cited herein.

One or more of the cited documents were identified in the international search report (enclosed) for this application.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 19036/40796. A duplicate copy of this paper is enclosed.

Dated: February 17, 2006

Respectfully submitted,

David A. Gass

Registration No.: 38,153

PEB 2 1 2006 W

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/561,629	
				Filing Date	21 June 2004 as PCT/JP2004/008710	
OTATEMENT BY ATTEIOANT			LIOAIII	First Named Inventor	Yuka Matsui	
	(Use as many sheets as necessary)			Art Unit	N/A	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	19036/40796	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		•				

		FOREI	GN PATENT	DOCUMENTS		$\neg$
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	B1	JP 2003-128583	05-08-2003	Rohto Pharmaceutical Co., Ltd.		$\Box$
	B2_	JP 2003-113078	04-18-2003	Lion Corp.		$\Box$
	B3	JP 2003-26575	01-29-2003	Rohto Pharmaceutical Co., Ltd.		
	B4	JP 2003-107416	04-09-2003	Lion Corp.		
	B5	JP 2003-183157	07-03-2003	Lion Corp.	•	$\Box$
	B6	JP 2003-201241	07-18-2003	Rohto Pharmaceutical Co., Ltd.		
	B7	JP 2003-190249	07-08-2003	Lion Corp.		$\Box$
	B8	JP 6-239748	08-30-1994	Senju Pharmaceut Co Ltd.		
	B9	JP 57-102817	06-26-1992	Kaken Pharmaceut Co. Ltd.		$\Box$
	B10	JP 56-39013	04-14-1981	Kaken Pharmaceut Co. Ltd.		
	B11.	JP 57-16817	01-28-1982	Kaken Pharmaceut Co. Ltd.		
	B12	JP 2001-261578	09-26-2001	Lion Corp.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	B13	International Search Report for International Application No. PCT/JP2004/008710 from the Japanese Patent Office dated 27 July 2004 (2 pages).		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.